First EZH2 Inhibitor Approved—for Rare Sarcoma
Unknown authors
Abstract
The FDA has approved tazemetostat for treating epithelioid sarcoma. The drug produced responses in 15% of patients with the disease in a phase II trial, and 67% of the responses lasted at least 6 months. The drug is the first targeted treatment for epithelioid sarcoma.
Topics & Concepts
Epithelioid sarcomaMedicineSarcomaDrugInternal medicineOncologyCancer researchPharmacologyPathologySarcoma Diagnosis and TreatmentVascular Tumors and AngiosarcomasLymphoma Diagnosis and Treatment